

# Immuno-Haematology Results in Behçet's Syndrome

Helen R Lock<sup>1,3</sup>, Bindi Gokani<sup>2</sup>, Sarah Sacoor<sup>2</sup>, Chris Scott<sup>3</sup>, Amal A Senusi<sup>1</sup>, Gonca Mumcu, William Ogunkolade<sup>1</sup> and Farida Fortune<sup>1,2</sup>

1 Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK <sup>2</sup> Behcet's Centre of Excellence, Royal London Hospital, Barts Health NHS Trust, UK <sup>3</sup> Department of Immunology, Royal London Hospital, East and South East London NHS Pathology Partnership, UK

#### Introduction

- Behçet's Syndrome (BS) is a rare systemic vasculitis of unknown aetiology characterised by recurrent orogenital aphthous ulcers & uveitis
- Little published work on routine Immunology and Haematology results in BS
- In this study we aim to compare lymphocyte subset, immunoglobulin G, A, M (IgGAM) and full blood count (FBC) results in BS patients to published reference ranges
  - Determine the relevance of measuring lymphocyte subsets, full blood count and immunoglobulins in patient management
  - Neutrophil-Lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and Systemic Immune Inflammation (SII) index calculated from measured FBC results

### **Methods**

- All methods verified and assessed to ISO 15189 standards
- Testing & analysis performed by HCPC-registered & competency-assessed Biomedical & Clinical Scientists at East and South East London (ESEL) Pathology Partnership

Samples taken from patients attending London Behçet's Centre of Excellence between August 2017 & December 2021 (table 1)

Test	Lymphocyte subsets	IgGAM	FBC	
Sample type	EDTA blood	Serum	EDTA blood	
Number of samples	909	796	852	
Number of patients	635	582	607	
ESEL department	Immunology	Clinical Chemistry	Haematology	
Method	Lyse no wash flow cytometry	Turbidimetry	Fluorescent flow cytometry	
Analyser	BD SPA II/BD Duet BD Canto II/BD Lyric	Roche Cobas c-207	Sysmex XN-2000	
Reference range	Comans-Bitter et al	Milford Ward	Dacie and Lewis	

Table 1: Summary of samples tested and analysis methods

## Results

At least one parameter was outside the reference ranges in 94% of all samples (n=909) (fig. 1) and 93% of first samples (n=635) (fig. 2)




Figure 1: Most results in all parameters were within range but all parameters had out-ofrange results

- At least 2 samples were received for 179 patients
- A comparison of longitudinal results on 1st and 2nd samples showed results were mostly stable with only a significant difference in T-sum (table 1)




Figure 2: Very similar distribution of out-of-range results when only results for the first sample received for patients were analysed.

The findings of this study of Immuno-Haematology results in this defined cohort were comparable to other available published studies (table 2)

Parameter	p value	
CD3 [%]	0.1582	
CD3 [Abs]	0.8603	
CD4 [%]	0.5322	
CD4 [Abs]	0.9208	
CD8 [%]	0.5279	
CD8 [Abs]	0.5649	
B [%]	0.5682	
B [Abs]	0.9045	
NK [%]	0.2463	
NK [Abs]	0.3547	
R4/8	0.3289	
T-sum	0.0049	
FBC lymphocytes	0.9246	
FBC neutrophils	0.0825	
FBC platelets	0.7406	
NLR	0.0740	
PLR	0.3470	
SII index	0.0861	
lgG	0.7168	
lg A	0.5168	
lgM	0.3450	

Table 1: 1st and 2nd results compared in 179 samples Only T-sum results were significantly different (p<0.005)

Parameter	Finding in this cohort	Literature	Comparison	
CD3 [%]	Raised in 32%, most within range	Within range, low		Table 2: Findings in this cohort were compared to published results. This is the first study comparing
CD3 [Abs]	Raised in 18%, most within range	Within range, low	No published studies on routine lymphocyte subset results	
CD4 [%]	Raised in 16%, most within range	Reduced		
CD4 [Abs]	Raised in 15%, most within range	Reduced		
CD8 [%]	Raised in 9%, most within range	Raised		
CD8 [Abs]	Raised in 11%, most within range	Raised		
B [%]	Reduced in 11%, most within range	Within range, reduced, raised		
B [Abs]	Reduced in 19%, most within range	Within range, reduced, raised		
NK [%]	Reduced in 41%, most within range	Reduced		
NK [Abs]	Reduced in 33%, most within range	Reduced		
R4/8	Reduced in 13%, most within range	Reduced		
T-sum	Raised in 22%, most within range	Reduced		
<b>FBC lymphocytes</b>	Reduced in 12%, most within range	Mostly within range	Agree	lymphocyte
FBC neutrophils	Raised in 17%, most within range	Often raised	Agree	subset and
FBC platelets	Raised in 4%, most within range	Often raised	Agree	FBC results
NLR	Raised in 23%, most within range	Raised	No otralico companias	in BS to published
PLR	Raised in 28%, most within range	Within range, raised	No studies comparing results to reference ranges	
SII index	Raised in 39%, most within range	Raised	results to reference ranges	reference
lg G	Raised in 5%, most within range	Mostly within range, raised in active disease	Agree	ranges.
lg A	Raised in 11%, most within range	Mostly within range, reduced in some patients	Agree	
lgM	Raised in 13%, most within range	Most within range	Agree	

ort ed to ed This rst ing cyte and sults ed

### **Discussion**

- At least one lymphocyte subset parameter outside of references ranges in 94% of all samples
- Results in this cohort support previously published results
- The similarity of longitudinal results suggests these tests should only be requested when treatment is changed
- The high number of samples with results outside reference ranges suggests that routine Immuno-Haematology profile testing is relevant to the management of BS
- Further analysis will aim to analyse the association of out-of-range results with symptom severity scores and investigate the impact of clinical outcomes on results and to propose a standardised Immuno-Haematology profile to aid in the management of BS patients









